PET predicts GI cancer's early response to chemo
F-18 FDG-PET can tell which patients will respond to neoadjuvant chemotherapy for advanced adenocarcinoma of the esophagogastric junction only two weeks after they begin treatment, according to a study released at the 2007 SNM meeting.
F-18 FDG-PET can tell which patients will respond to neoadjuvant chemotherapy for advanced adenocarcinoma of the esophagogastric junction only two weeks after they begin treatment, according to a study released at the 2007 SNM meeting.
German investigators evaluated 110 patients who underwent FDG-PET to assess response to chemotherapy. Researchers defined as responders patients with 35% or greater decrease in tumor standardized uptake value after two weeks of treatment. Responders went on chemotherapy for 12 weeks before surgery, while nonresponders discontinued treatment and proceeded to surgery right away.
Researchers found statistically significant evidence (p < .002) that responders survived about twice as long as nonresponders during a median follow-up of 2.3 years.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
